Eli Lilly's (LLY) Jaypirca is now approved and available in Canada for adult patients with relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia, Eli Lilly Canada announced Tuesday.

The drug has received the notice of compliance with conditions by Health Canada based on the response rate from the phase 1/2 study, called the BRUIN trial, the company said.

The pirtobrutinib tablet is approved as an oral prescription medicine in 100 mg or 50 mg taken as a once-daily 200 mg dose.

Price: 1050.82, Change: -11.93, Percent Change: -1.12